⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928292 | 0.79 | — | — | |
| SCHEMBL23928302 | 0.79 | — | — | |
| SCHEMBL112619 | 0.79 | — | — | |
| SCHEMBL207087 | 0.75 | — | — | |
| SCHEMBL29427025 | 0.73 | — | — | |
| SCHEMBL10316967 | 0.72 | — | — | |
| SCHEMBL23826945 | 0.71 | — | — | |
| SCHEMBL14165283 | 0.71 | — | — | |
| SCHEMBL165170 | 0.70 | — | — | |
| SCHEMBL20512584 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4236937-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| WO-2022093849-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| EP-3019493-B1 | MODIFIED BET-PROTEIN INHIBITING DIHYDROCHINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | Bayer Pharma AG (DE) | 2017-06-14 | — | — | EP | claimed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | claimed |
| US-11945799-B2 | 4-ethynylpyridine derivatives useful as GCN2 inhibitors | IP2IPO INNOVATIONS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| WO-2023218195-A1 | GCN2 INHIBITORR | IP2IPO INNOVATIONS LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| EP-4161915-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO Innovations Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
| WO-2021250399-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2021-12-16 | — | — | WO | disclosed |
| US-11161830-B2 | 4-pyridone compound or salt thereof, and pharmaceutical composition and formulation including same | FUJIFILM CORPORATION (JP) | 2021-11-02 | — | — | US | disclosed |
| EP-3604301-B1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM CORP (JP) | 2021-09-22 | — | — | EP | disclosed |
| EP-3604301-A1 | 4-PYRIDONE COMPOUND OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION AND FORMULATION INCLUDING SAME | FUJIFILM Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20160176867-A1 | MODIFIED BET-PROTEIN-INHIBITING DIHYDROQUINOXALINONES AND DIHYDROPYRIDOPYRAZINONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-2970281-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014172044-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |